Date: 2016-04-21
Type of information: Company acquisition
Acquired company: Exquiron Biotech (Switzerland)
Acquiring company: Aptuit (UK)
Amount: undisclosed
Terms: * On April 21st, 2016, Aptuit announced that it has acquired Exquiron Biotech to meet customer demand for fully integrated outsourced discovery services. Aptuit provides a set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including drug design & discovery, API development and manufacture, solid state chemistry, CMC, preclinical and IND enabling GLP/GMP programs.
Details: Exquiron is located near Basel and was founded in 2013. The company is dedicated to state-of-the-art hit identification and validation services for pharmaceutical drug discovery and nutraceuticals. Exquiron's expertise includes assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.
Related: Technology - Services
